Skip to main content
SP5007,798.99+0.65%DOW53,839.99+0.13%NASDAQ26,803.03+0.81%BTC$63,483.00-0.06%ETH$1,886.42+0.31%GOLD$4,396.70-0.54%OIL$81.15-0.12%
Smart Investors Daily
Sign InSign Up Free
PC

NASDAQ · PCSA

Processa Pharmaceuticals, Inc.

Healthcare · Biotechnology

$2.56

Down-$0.06 (-2.34%)

Updated Aug 14, 2026, 1:10 AM

SID Score

5.2/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
15.65M
P/E ratio
-1.01
Dividend yield
0.00%
52-week range
$1.67 – $3.45
Volume
82.68K
Avg. volume
9.87M

Price performance

PCSA price history

1M range · 20 trading sessions · Daily adjusted prices

PCSA closed at $2.56 after 20 trading sessions, up 14.29% for the selected period.

Last close
$2.56
Period change
+14.29%
Period low
$2.03
Period high
$3.05
Daily close
View OHLC price history
PCSA OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Aug 12, 2026$2.625$2.68$2.46$2.5682.68K
Aug 11, 2026$2.62$2.68$2.57$2.6345.62K
Aug 10, 2026$2.61$2.79$2.56$2.6177.7K
Aug 7, 2026$2.36$2.64$2.32$2.57113.05K
Aug 6, 2026$2.18$2.38$2.18$2.3073.09K
Aug 5, 2026$2.10$2.25$2.10$2.1965.8K
Aug 4, 2026$2.08$2.31$2.07$2.12151.91K
Aug 3, 2026$2.05$2.22$2.05$2.1398.43K
Jul 31, 2026$2.00$2.20$1.92$2.15395.9K
Jul 30, 2026$1.91$2.18$1.9001$2.04456.99K
Jul 29, 2026$1.83$2.35$1.80$2.0310.61M
Jul 28, 2026$2.65$3.11$2.5217$3.05141.74K
Jul 27, 2026$2.69$2.7443$2.5312$2.5961.35K
Jul 24, 2026$2.76$2.87$2.52$2.60129.52K
Jul 23, 2026$2.538$2.89$2.50$2.87104.36K
Jul 22, 2026$2.31$2.60$2.23$2.54112.19K
Jul 21, 2026$2.22$2.35$2.15$2.2497.88K
Jul 20, 2026$2.30$2.3028$2.205$2.2243.05K
Jul 17, 2026$2.25$2.335$2.18$2.3148.14K
Jul 16, 2026$2.295$2.35$2.24$2.2454.29K

Latest PCSA news

The latest Smart Investors Daily articles mentioning PCSA.

Stock researchCompany · Overview

PCSA research

Overview

Company profile and research snapshot.

Company profile

Processa Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on utilizing its regulatory science approach in the development of Next Generation Chemotherapy (NGC) oncology drug products. The company's strategic prioritization is to advance its pipeline of NGC proprietary small-molecule oncology drugs. The NGC products are new chemical entities, but the company works by changing the metabolism, distribution, and/or elimination of already FDA-approved cancer drugs or their active metabolites while maintaining the mechanism of how the drug kills cancer cells. The three NGC treatments in its pipeline are PCS6422 (also referred to as NGC-Cap), PCS3117, also referred to as NGC-Gemcitabine (NGC-Gem), and PCS11T, also referred to as NGC-Irinotecan (NGC-Iri).

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Buy
Average target
$9.00
Implied upside
—
Analysts
8
PCSA recent ratings
DateFirmRatingTarget
Sep 2, 2025HC Wainwright & Co.Buy—
Jun 30, 2025HC Wainwright & Co.Buy—
Dec 5, 2024HC Wainwright & Co.Buy—
Oct 3, 2024HC Wainwright & Co.Buy—
Aug 20, 2024HC Wainwright & Co.Buy—
Open full forecast

News briefing

No generated briefing is available yet.

globenewswire.com · Nov 5, 2025

Processa Pharmaceuticals Announces Poster Presentation of Adaptive Phase 2/3 PCS499 Study in FSGS at ASN Kidney Week 2025

VERO BEACH, Fla., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA), a clinical-stage biopharmaceutical company developing Next Generation Cancer (NGC) therapies and innovative treatments for rare diseases, today announced that its abstract, “Adaptive Phase 2/3 Study for PCS499 (499) in Patients with Focal Segmental Glomerulosclerosis (FSGS)”, has been accepted for presentation at the American Society of Nephrology (ASN) Kidney Week 2025, taking place November 5–9, 2025, in Houston, Texas.

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By